Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other diseases involving protein growth factors, has scheduled a conference call for February 27, 2025, at 8:15am ET. The call will cover fourth quarter and full-year 2024 financial results along with a business update.
The company will provide multiple ways to access the call, including a live audio webcast available through the Investor Relations section of Scholar Rock's website. An archived replay will remain accessible on the website for approximately 90 days after the event.
Scholar Rock (NASDAQ: SRRK), una compagnia biofarmaceutica in fase avanzata focalizzata sui trattamenti per la atrofia muscolare spinale (SMA), i disturbi cardiometabolici e altre malattie legate ai fattori di crescita proteici, ha programmato una conferenza telefonica per il 27 febbraio 2025, alle 8:15 ET. La chiamata coprirà i risultati finanziari del quarto trimestre e dell'intero anno 2024, insieme a un aggiornamento sull'attività dell'azienda.
L'azienda fornirà diverse modalità per accedere alla chiamata, incluso un webcast audio in diretta disponibile attraverso la sezione Relazioni con gli Investitori del sito web di Scholar Rock. Una registrazione archiviata sarà accessibile sul sito per circa 90 giorni dopo l'evento.
Scholar Rock (NASDAQ: SRRK), una compañía biofarmacéutica en etapa avanzada enfocada en tratamientos para la atrofia muscular espinal (SMA), trastornos cardiometabólicos y otras enfermedades relacionadas con factores de crecimiento proteicos, ha programado una llamada de conferencia para el 27 de febrero de 2025, a las 8:15 am ET. La llamada cubrirá los resultados financieros del cuarto trimestre y del año completo 2024, junto con una actualización empresarial.
La compañía proporcionará múltiples formas para acceder a la llamada, incluyendo una transmisión de audio en vivo disponible a través de la sección de Relaciones con Inversores del sitio web de Scholar Rock. Una repetición archivada estará accesible en el sitio durante aproximadamente 90 días después del evento.
Scholar Rock (NASDAQ: SRRK)는 척수 근위축증(SMA), 심혈관 대사 장애 및 단백질 성장 인자가 관련된 기타 질병에 대한 치료법에 중점을 둔 후기 단계 바이오 제약 회사로, 2025년 2월 27일 오전 8:15 ET에 콘퍼런스 콜을 예약했습니다. 이 통화에서는 2024년 4분기 및 전체 연도 재무 결과와 함께 회사의 업데이트가 포함될 것입니다.
회사는 Scholar Rock 웹사이트의 투자자 관계 섹션을 통해 이용할 수 있는 라이브 오디오 웹캐스트를 포함하여 통화에 접근할 수 있는 여러 가지 방법을 제공할 것입니다. 이벤트 이후 약 90일 동안 웹사이트에서 보관된 재생을 계속해서 이용할 수 있습니다.
Scholar Rock (NASDAQ: SRRK), une entreprise biopharmaceutique en phase avancée axée sur les traitements de l'atrophie musculaire spinale (SMA), des troubles cardiométaboliques et d'autres maladies impliquant des facteurs de croissance protéiques, a programmé une conférence téléphonique pour le 27 février 2025 à 8h15 ET. L'appel couvrira les résultats financiers du quatrième trimestre et de l'année entière 2024, accompagné d'une mise à jour sur les activités de l'entreprise.
L'entreprise proposera plusieurs moyens d'accéder à l'appel, y compris une diffusion audio en direct disponible via la section Relations Investisseurs du site Web de Scholar Rock. Une rediffusion archivée sera accessible sur le site pendant environ 90 jours après l'événement.
Scholar Rock (NASDAQ: SRRK), ein biopharmazeutisches Unternehmen in der späten Entwicklungsphase, das sich auf Behandlungen für spinale Muskelatrophie (SMA), kardiometabolische Störungen und andere Erkrankungen mit Wachstumsfaktoren für Proteine konzentriert, hat eine Telefonkonferenz für den 27. Februar 2025, um 8:15 Uhr ET angesetzt. Die Konferenz wird die finanziellen Ergebnisse des vierten Quartals und des gesamten Jahres 2024 sowie ein Update zum Geschäft umfassen.
Das Unternehmen bietet mehrere Möglichkeiten, auf die Konferenz zuzugreifen, einschließlich eines Live-Audio-Webcasts, der über den Bereich Investor Relations auf der Website von Scholar Rock verfügbar ist. Eine aufgezeichnete Wiederholung wird für ungefähr 90 Tage nach der Veranstaltung auf der Website zugänglich bleiben.
- None.
- None.
To access the live conference call, participants may register here. The live audio webcast of the call will be available under “Events and Presentations” in the Investor Relations section of the Scholar Rock website at http://investors.scholarrock.com. To participate via telephone, please register in advance here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. An archived replay of the webcast will be available on the Company’s website for approximately 90 days.
About Scholar Rock
Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role.
This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about our approach at ScholarRock.com and follow @ScholarRock and on LinkedIn.
Scholar Rock® is a registered trademark of Scholar Rock, Inc.
Availability of Other Information About Scholar Rock
Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250210252556/en/
Scholar Rock:
Investors
Rushmie Nofsinger
Scholar Rock
rnofsinger@scholarrock.com
ir@scholarrock.com
857-259-5573
Media
Molly MacLeod
Scholar Rock
mmacleod@scholarrock.com
media@scholarrock.com
802-579-5995
Source: Scholar Rock
FAQ
When will Scholar Rock (SRRK) report Q4 and full-year 2024 earnings?
How can investors access Scholar Rock's (SRRK) Q4 2024 earnings call?
How long will Scholar Rock's (SRRK) Q4 2024 earnings call replay be available?
What therapeutic areas does Scholar Rock (SRRK) focus on?
